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Anemia is common in elective surgery and is an independent risk factor for morbidity and 
mortality. Historical management of anemia has focused on the use of allogeneic blood transfusion 
but this in itself is not without risk. It too has been independently associated with morbidity and 
mortality, let alone the costs and relative shortage of this resource. In recognition of this, patient 
blood management shifts the focus from the product to the patient and views the patient’s own 
blood as a resource that should be conserved and managed appropriately as a standard of care. It 
consists of three pillars: the optimization of red blood cell mass; reduction of blood loss and 
bleeding; and optimization of the patient’s physiological tolerance towards anemia. Integration of 
these three pillars in the form of multimodal care bundles and strategies into perioperative pathways 
should improve care processes and patient outcome.  
 
Preoperative anemia is most commonly caused by functional iron deficiency and should be treated 
with oral iron, intravenous iron and/or recombinant erythropoietin. An individualized assessment of 
the thrombotic risk of discontinuing anticoagulant and antiplatelet medication should be balanced 
against the risk of perioperative bleeding. Neuraxial anesthetic techniques should be considered and 
minimally invasive surgery undertaken where appropriate. Cell salvage should be used if significant 
blood loss is anticipated and pharmascological treatments such as tranexamic acid and fibrin 
sealants have been shown to reduce blood loss. Point of care tests can guide the perioperative 
management of dynamic coagulopathy. Blood testing sampling should be performed only when 
indicated and when taken, sample volume and waste should be minimized. Restrictive blood 
transfusion thresholds and re-assessment after single unit transfusion should be incorporated into 





Anemia is common and is associated with significant morbidity and mortality.1 In the past, 
transfusion practice in the perioperative period focused on the use of allogeneic blood to treat and 
correct anemia which was culturally embedded as default therapy. It has become increasingly clear 
however that allogeneic blood transfusion (ABT) itself is an independent risk factor for poor 
clinical outcomes.2 Moreover, the cost of transfusion continues to escalate and the gap between 
supply and demand of this scarce resource is ever widening.3 In response to these drivers, there has 
been a paradigm shift from a product focus to a patient focus in transfusion medicine.  
 
Patient blood management (PBM), defined by the Society for the Advancement of Blood 
Management (SABM), is the timely application of evidence-based medical and surgical concepts 
designed to maintain hemoglobin (Hb) concentration, optimize hemostasis and minimize blood loss 
in an effort to improve patient outcomes. It rejects the standard dogma which considers red blood 
cell (RBC) transfusion to be the primary solution in the correction of anemia and views the patient’s 
own blood as a resource that should be conserved and managed appropriately as a standard of care. 
PBM can be seen as consisting of three pillars, the optimization of RBC mass, reduction of blood 
loss and bleeding, and optimization of the patient’s physiological tolerance towards anemia.4 
Patient-centred decision-making is crucial when determining an individualized management plan 
and involves the communication of the risks and benefits of the various potential interventions to 
decide upon the right course of action.  
 
In 2010, PBM was adopted by the World Health Organization (WHO) and it is supported by NHS 
Blood and Transplant (NHSBT) and the National Blood Transfusion Committee in the UK. Started 
at the earliest opportunity prior to surgery and continued into the postoperative period, PBM 
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addresses the triad of independent risk factors that can affect outcome in surgical patients, namely 
anemia, blood loss and transfusion. It is in the setting of elective surgery where the most evidence 
for benefit of PBM has been demonstrated in reducing exposure to ABT and improving patient 
outcomes.5 
 
In this article, we will review the outcomes associated with anemia and ABT and consider how the 
three pillars of PBM can provide a structure for multidisciplinary and multimodal care bundles and 
strategies that can be instituted into perioperative pathways with the aim of improving patient 
outcome.  
 
Anemia: definition, causes and outcomes 
 
Since 1968, the WHO has defined anemia as an insufficient circulating red cell mass with a Hb 
level <13 g/dL in males and <12 g/dL in menstruating females.6 More than 30% of the world’s 
population are anemic but the incidence varies with age and comorbidity. In the US National 
Surgery Quality Improvement Program (NSQIP), the prevalence of anemia in patients undergoing 
surgery was 30.4%1 while in Europe, it was found to be 28.7%.7 Estimates of anemia in surgical 
patients range widely as the underlying surgical condition can predispose the patient to anemia, 
from 5% in elderly females with hip fracture to 75.8% in Dukes stage D colon cancer.8 
Postoperative anemia is more common than preoperative anemia and can be present in up to 90% of 
patients after major surgery.8   
 
Anemia has multiple different causes such as hemoglobinopathy, nutritional deficiencies and renal 
failure. One of the most prominent causes is iron deficiency9 and can be either absolute or 
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functional. In a 70 kg male, total body iron is about 3500 mg, of which most (65%) is found in Hb 
within the RBC and much of the remainder is stored in the liver, macrophages and bone marrow.10  
 
In absolute iron deficiency, there is a reduction in the total body iron which can either be present in 
isolation, when the level of erythroid iron is still sufficient for erythropoiesis, or in conjunction with 
anemia. In functional iron deficiency, in contrast, there is iron-restricted erythropoiesis despite 
normal or even increased total body iron. Inflammation, whether caused by autoimmune 
mechanisms, infection or malignant cells, can result in functional iron deficiency secondary to its 
activation of hepcidin and thus functional iron deficiency is the most common cause of anemia of 
chronic disease.11 Hepcidin is an amino acid glycoprotein produced in the liver whose normal role 
is act on ferroportin, a transmembrane iron transporter found in duodenal enterocytes and 
macrophages. Degradation of ferroportin by activated hepcidin prevents enteral iron absorption and 
transport of iron from the liver, where it is stored as ferritin, and macrophages to the plasma. 
Consequent to this, binding of transferrin, the plasma iron transport protein, to iron is reduced and 
less iron is delivered to the bone marrow affecting effective erythropoiesis.12 
 
Of concern, anemia is an independent risk factor for perioperative morbidity and mortality in 
cardiac13-16 and non-cardiac surgery17-19 and is not just a laboratory value but also a disease in itself. 
Mild anemia leads to impaired functional capacity and performance and a reduced quality of life.20  
 
In a retrospective cohort study, which used data from the American College of Surgeons’ NSQIP, 
the effect of mild and moderate-severe anemia was evaluated in 227,425 patients undergoing 
elective major non-cardiac surgery.1 Preoperative anemia was associated with a 35% increased odds 
ratio of composite postoperative morbidity and a 42% increased odds ratio of mortality at 30 days. 
Of note, this relationship was present for mild anemia as well. Data from NSQIP was used again to 
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study the effect of anemia in 23,348 patients who underwent elective open and laparoscopic 
colectomies.21 Preoperative anemia, even if mild, was found to be a risk factor for a composite 
outcome consisting of myocardial infarction, stroke, progressive renal insufficiency or death within 
30 days of operation and to correlate with a longer hospital length of stay (LOS). Further studies 
have continued to use NSQIP data to demonstrate the association between anemia and adverse 
outcomes.22,23 More recently, a secondary analysis of non-cardiac and non-neurological surgery in 
39,309 patients which included elective and non-elective cases showed that moderate and severe 
anemia resulted in increased postoperative admission to intensive care, hospital LOS and in-hospital 




Compared to comorbidities and severity of illness, anemia is a strong predictor of the likelihood of 
ABT.24 ABT has been traditionally used to correct anemia with insufficient consideration of the 
underlying cause or the associated risks and benefits. If the cause is not addressed, which in most 
cases is chronic and ongoing in nature, the correction is likely to be transient and the anemia may 
recur. Considerable variations in transfusion practice have underlined the need for appropriate 
transfusion use. In orthopedic surgery, for example, the ABT rate varies from 1.5% to 78% for total 
hip replacement.25 Indication for ABT should take into consideration patient specific factors, 
laboratory values, physiological factors and the presence or absence of bleeding. In the emergency 
setting of acute hemorrhage, ABT could however be the treatment of choice. 
 
In the most recent report from the Serious Hazards of Transfusion (SHOT), 166 patients suffered 
major morbidity and 26 died, two of which were definitely related, nine probably related and fifteen 
possibly related to transfusion.26 Complications from transfusion included acute and hemolytic 
 8 
transfusion reactions, circulatory overload, dyspnea, transfusion-transmitted infection and 
transfusion-related acute lung injury (TRALI).  
 
Similar to anemia, ABT is an independent risk factor for perioperative morbidity and mortality.27-29 
In a prospective study that used NSQIP to collect data from 6301 patients undergoing non-cardiac 
surgery, ABT was associated with increased postoperative pneumonia, hospital LOS and 
mortality.30 Multiple subsequent studies included an increasing number of patients and confirmed 
the dose dependent relationship between ABT and a composite outcome of myocardial infarction or 
stroke, pulmonary, renal, septic, thromboembolic and wound complications, and increased hospital 
LOS.31-34 Consistent with the results of previous studies, a systematic review of observational 
studies concluded that ABT does have an adverse effect on mortality but could not exclude the 
possibility that confounding secondary to unknown and hence unadjusted factors still played a 
role.33  
 
Concerns have also been raised about the influence of ABT on immunomodulation and 
postoperative infection, metastasis and the recurrence of cancer.35-43 Immunomodulation of the 
innate and adaptive immune system occurs after exposure of the recipient to the many cell bound 
and soluble antigens expressed on viable and decaying cells in the transfusion.44 In particular, 
contaminant leukocytes are thought to have a significant role. ABT has been associated with 
infectious complications after operations for gastrointestinal and pancreatic cancer, hip replacement 
and spinal fusion.35-38 Moreover, a systematic review demonstrated that the odds ratio of 
postoperative bacterial infection was 3.45 subsequent to ABT.39 It has been widely reported that 
perioperative blood transfusions increase the risk of colorectal cancer recurrence.40-42 A Cochrane 
meta-analysis examined this association in 12,127 patients from 36 trials.43 It showed that blood 
transfusion was related to a 42% increase in the odds ratio for cancer recurrence in a dose-related 
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manner and thus recommended that ABT should be restricted in its use in patients with curable 
colorectal cancer. Similar trends in recurrence have been found with the use of blood transfusion in 
surgical patients with various other cancers.45-48 
 
Importantly, transfusion is costly and the cost of transfusing a RBC unit, including consumables and 
labor, is approximately four times higher than to purchase the product.49,50 In the UK, after 
including derived costs such as hospital stay, the mean cost for a transfusion of two units in 
hematology and oncology patients was determined to be £546.12.51 Evaluation of the cost of blood 
in a surgical population at two European and two US hospitals found each RBC unit to cost 
between $522 and $1183.50 Annual expenditures on blood and transfusion-related activities, limited 
to surgical patients, ranged from $1.62 to $6.03 million per hospital and were largely related to the 
transfusion rate.  
 
1st Pillar: optimization of red blood cell mass 
 
In the preoperative period, laboratory investigations should be performed as soon as possible if 
moderate to high blood loss, defined as more than 500 ml is likely, or there is a ≥10% probability 
for ABT.52 They should include a full blood count, serum ferritin, transferrin saturation (TSAT), a 
marker of inflammation such as C-reactive protein (CRP) and a surrogate of renal function. 
Guidelines from the Network for Advancement of Transfusion Alternatives (NATA) advocate that 
the level of Hb should be measured 28 days before elective orthopedic surgery53 while those from 
European Society of Anaesthesiology recommend that patients at risk of bleeding be assessed for 
anemia 4-8 weeks before surgery.54 In our view, females should be optimized to the same level of 
Hb as males to 13 g/dL despite the WHO definition of anemia. Both sexes lose comparable amounts 
of blood in similar surgical procedures but females have a relatively lower circulating volume 
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which means they lose proportionally more. Females could therefore be at otherwise increased risk 
of ABT which has been corroborated by the results of previous studies.55,56  
 
Treatment of anemia should be directed at the cause. In the case of iron deficiency anemia, either 
oral or intravenous iron can be used. Oral iron is low cost and a recent meta-analysis demonstrated 
that it increases the Hb and decreases the proportion of patients who require ABT.57 Notably 
however, the bioavailability of ferrous iron is only 10-15% and this may be reduced further by the 
stimulation of hepcidin in inflammatory conditions. Enteral iron is absorbed at a rate of 2-16 mg per 
day and if the iron deficit which needs to be replaced is significant, it could take too long for oral 
iron to effectively replenish stores. Compliance can be a problem as well because of gastrointestinal 
side effects such as abdominal pain, constipation and diarrhea.58 Interestingly, high doses of oral 
iron sulphate in iron deficient but non-anemic females stimulate hepcidin and result in lower iron 
absorption from the next daily dose. Administration of low dose oral iron on alternate days may 
increase fractional iron absorption, maximize dosage efficacy, reduce gastrointestinal exposure to 
unabsorbed iron and improve adherence to treatment.59 Once oral iron has been commenced, the Hb 
should be measured again, at least four weeks before surgery.  
 
If there has not been an increment in the Hb with oral iron, the patient is intolerant of it or surgery is 
scheduled in less than six weeks time, intravenous (IV) iron is preferred. Compared to oral iron, IV 
iron is more effective in raising the level of Hb.57 In the context of hepcidin up-regulation, IV iron 
may be more likely to work as it is taken up by macrophages and degraded leading to an increase in 
intracellular iron.60 Intracellular iron increases ferroportin expression, partly overcoming hepcidin 
blockade and allowing iron to be transported by transferrin in the plasma to the bone marrow for 
erythropoiesis. In multiple studies, IV iron has been associated with a decrease in the need for ABT, 
a fall in the incidence of acute kidney injury and infections, and a reduction in the hospital LOS.61-63  
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Currently, six different formulations of IV iron are available in Europe and the US (Table 1). 
Depending on the preparation, the dose can be administered in as little as 15 minutes which is more 
acceptable to the patient as it incurs fewer hospital visits. A recent meta-analysis demonstrated that 
IV iron, when compared to oral or intramuscular iron, no iron or placebo, was not associated with 
an increase in the risk of infection or serious adverse events (SAEs) but did reduce the risk of 
adverse gastrointestinal events.64 Serious adverse reactions and death are very rare, occurring in 38 
per 106 and 0.4 per 106 administrations respectively.65 In a comparison of the cost of IV iron versus 
ABT, which included consideration of acquisition, administration and transport costs, IV iron was 
found to be more cost effective.66  
 
Use of recombinant erythropoietin (rEPO) to act on progenitors in the bone marrow and stimulate 
erythropoiesis first became widespread in dialysis patients.67 A meta-analysis of an overall small 
sample size evaluated the effect of rEPO in colorectal cancer surgery and demonstrated no 
significant change in the level of Hb nor the number of units transfused per patient.68 Subsequent 
meta-analyses in patients undergoing cardiac or orthopedic surgery have found that rEPO increased 
the level of Hb56 and reduced the risk of ABT.69-72 Guidelines from NATA recommend that, in the 
setting of orthopedic surgery, rEPO should be used for anemic patients in whom nutritional 
deficiencies have been corrected or excluded.53 In one systematic review, subgroup analysis showed 
that variation in the dose and route of administration of rEPO had no effect on the risk of ABT.69 
Definitive conclusions however about the optimal dose, duration of treatment and route of 
administration of rEPO cannot be reached because of the significant heterogeneity in the scheduling 
pattern of rEPO in the individual clinical trials in these meta-analyses. Of note, rEPO has been 
associated with hypertension and ischemic and thrombotic events, possibly secondary to the 
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rapidity of rise and potential overshoot in Hb concentration as well as the trophic effect of rEPO on 
other cells.73 
 
2nd Pillar: reduction of blood loss and bleeding 
 
A standardized history to assess the risk of bleeding should be taken. It should ascertain as to 
whether there is a past history of bleeding after surgery or trauma, menorrhagia in females, drug 
history related to anticoagulant and antiplatelet medication, and a family history of bleeding 
diathesis. Increasingly, anticoagulant and antiplatelet medication is being continued into the 
perioperative period. An individualized assessment of the thrombotic risk of discontinuing these 
medications should be balanced against the risk of perioperative bleeding.  
 
Surgical blood loss is decreased with neuraxial techniques relative to general anesthesia, probably 
secondary to a fall in blood pressure and venous tone resulting from sympathetic blockade.74 
Compared to open and invasive surgery, laparoscopic and minimally invasive surgical techniques, 
such as robotic gastrectomy, are associated with reduced surgery-related blood loss.75,76 Judicious 
use of diathermy dissection and meticulous hemostasis is crucial. The patient should be positioned 
in such a way that venous return is not obstructed which could otherwise increase venous pressure 
and therefore bleeding at the operative site. Cardiovascular physiology should be manipulated as 
appropriate to limit bleeding. In hepatic resection, for example, the central venous pressure can be 
lowered. Maintenance of normothermia and avoidance of acidosis and hypocalcemia is key in the 
optimization of hemostatic conditions.77  
 
Conventional coagulation tests can in certain circumstances be misleading and have an 
unacceptably long response time in dynamic situations.78,79 Viscoelastic tests (VET), in contrast, are 
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performed at the point of care and can direct the perioperative management of coagulopathy. Both 
thromboelastography® (TEG®) and thromboelastometry® (ROTEM®) measure changes in clot 
tensile strength over time and provide information on the kinetics of clot formation and dissolution 
within 10-20 minutes.80 Specific patterns of VET measurements can guide the administration of 
fresh frozen plasma, platelets, cryoprecipitate, factor concentrates and antifibrinolytics. Use of VET 
has been advocated in cardiac surgery by the National Institute for Health and Care Excellence 
(NICE) in the UK,81 where a meta-analysis found it to decrease the need for transfusion in those 
patients at risk of coagulopathic bleeding.82 It did not however decrease mortality, reoperation for 
bleeding, stroke, ventilation time or hospital LOS. In other meta-analyses, where most included 
studies were undertaken in the setting of cardiac surgery, transfusion requirements were also 
similarly reduced,83,84 but in one the use of VET was associated with a reduction in overall 
mortality.84   
 
Pharmacological treatments have demonstrated benefit in reducing perioperative blood loss. Epsilon 
aminocaproic acid (EACA) and tranexamic acid (TXA) are analogues of the amino acid lysine and 
reversibly inhibit fibrinolysis by binding the lysine-binding sites on plasminogen, limiting the 
activation of plasmin which degrades fibrin.85 A meta-analysis of EACA and TXA in the setting of 
elective surgery found that the evidence was stronger for TXA than for EACA with a relative risk 
reduction of 39% and 25% respectively in the need for ABT.86 Early use of TXA in trauma has 
been associated with a reduction in mortality due to bleeding and all-cause mortality.87 Because the 
hemostatic responses to surgery and trauma are similar, TXA might reduce mortality due to 
bleeding in surgical patients.88 TXA can also be used in topical form where a systematic review 
showed that it reduced blood loss by 29% and the relative risk of receiving a blood transfusion by 
45% in cardiothoracic, oral, orthopedic, otorhinolarnygeal, spinal and urological surgery.89   
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Other topical hemostatic agents include fibrin sealants which contain fibrinogen (with or without 
factor XIII) and thrombin (with calcium) and mimic the final phase of the coagulation cascade.90 
Previously, a meta-analysis demonstrated that fibrin sealant decreased relative exposure to ABT by 
54%91 and a more recent systematic review showed a reduced ABT and blood loss in orthopedic 
surgery.92  
 
Cell salvage is an established technique in cardiac, orthopedic and major vascular surgery93,94 and 
should be considered where the anticipated blood loss is greater than 1000 ml.95 It is performed 
with the use of a double lumen suction device to collect blood. Blood is stored within a reservoir 
with added anticoagulant and once enough blood is collected, the RBCs are washed, filtered, 
suspended in saline to be returned to the patient. Re-transfused RBCs from cell salvage have no 
clotting factors, platelets or plasma and so additional hemostatic therapies may be required. Use of 
cell salvage reduces the relative rate of ABT by 38%, saving an average of 0.68 of allogeneic RBCs 
per patient,92 and it is cost effective compared with transfusion.96 Though there have been concerns 
about the harmful effects of bacteria and malignant cells aspirated from the surgical field, studies 
have shown that there is no increase in positive culture or postoperative infection despite the 
aspiration of blood contaminated with microorganisms which the washing process is unable to 
eliminate completely.97,98  
 
Acute normovolemic hemodilution (ANH) is the practice of preoperative withdrawal of whole 
blood with concurrent infusion of fluids to maintain normovolemia. Potential benefits of ANH 
include improvement in tissue oxygenation because of decreased blood viscosity, dilution of 
circulating components reducing the red cell mass lost due to surgical bleeding and the availability 
of whole blood for re-transfusion at the conclusion of surgery. ANH may be more cost effective 
than cell salvage96 and though a recent meta-analysis has suggested that ANH is effective in 
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reducing ABT, these conclusions were limited by the significant identified heterogeneity and 
publication bias.99 
 
In the postoperative period, efforts to avoid coagulopathy and reduce bleeding should be continued. 
Cell salvage can be used after the operation95 but surgical drains can increase the rate of ABT in 
orthopedic surgery100 though its use is declining with the establishment of enhanced recovery 
programmes. Repeated blood sampling can result in iatrogenic blood loss, contribute to 
postoperative anemia and should be minimized. In cardiac surgery, cumulative median phlebotomy 
volume for the hospital stay was 454 ml and increased with LOS.101 Patients with similar risk 
factors for mortality in the intensive care environment were subjected to more blood tests if they 
had an indwelling arterial catheter.102 Because of this, non-invasive monitoring should be 
considered where appropriate. Blood tests should be performed only when indicated and when 
taken, the smallest collection tube size that is practical for the required analysis should be used. In a 
study, replacement of adult blood tubes with pediatric ones reduced blood loss associated with 
diagnostic testing by 47%.103 Transition to the use of pediatric blood tubes is not however simple as 
the patient identification labels are often larger than the tube, process costs are higher and the 
analysis can be delayed. Discard volume should be as low as possible and blood waste minimized 
by the use of closed in-line flush blood sampling devices for arterial and central venous devices.104  
 
3rd Pillar: optimization of the patient’s physiological tolerance towards anemia 
 
Oxygen uptake, transport, delivery and utilization are complex biological processes and any 
deficiency in any link in this chain, such as anemia, can be compensated for by other links.105 
Adaptive responses include increased minute ventilation and cardiac output, improved ventilation-
perfusion in the lungs, preferential oxygen delivery to vital organs and higher tissue oxygen 
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extraction. A patient’s physiological tolerance of anemia can be harnessed in several ways.106 
Oxygenation can be optimized by increasing the inspired fraction of oxygen and hemodynamics can 
be manipulated with the use of vasopressors to maintain organ perfusion. Consumption of oxygen 
can be decreased by ensuring adequate analgesia and minimizing infection.   
 
Evidence suggests that transfusion with RBCs fails to improve tissue oxygenation within the first 24 
hours and might in fact decrease it.107,108 In the seminal Transfusion Requirements in Critical Care 
(TRICC) trial, a restrictive strategy with a transfusion threshold of less than 7 g/dL was as effective 
as a liberal strategy with a transfusion threshold of less than 10 g/dL in 838 critically ill patients.109 
Further studies have supported these findings and a restrictive threshold of less than 8 g/dL was 
compared to a liberal transfusion threshold of less than 10 g/dL in patients with a history of or risk 
factors for cardiovascular disease who were undergoing hip fracture surgery.110,111 A restrictive 
transfusion strategy did not reduce functional capacity or increase 60 day and long-term mortality. 
Multiple meta-analyses have shown that the use of a restrictive transfusion threshold across a broad 
range of specialities does not impact adversely on morbidity and mortality compared to a liberal 
transfusion threshold.112-114  
 
In recognition that restrictive transfusion thresholds are non-inferior to liberal ones, NICE 
advocates that RBC transfusion should be considered at a Hb threshold of 7 g/dL in patients who do 
not have acute coronary syndrome or major hemorrhage, aiming for a target concentration of 7-9 
g/dL after transfusion.115 After each single unit of RBC transfusion, a clinical re-assessment should 
be made and the level of Hb checked to evaluate the appropriateness of further transfusion. Such 
practice could improve RBC utilization and decrease patient exposure to ABT.116  
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Patients with cardiovascular disease could represent a specific high risk group at the limits of their 
physiological reserve for which liberal transfusion thresholds should be recommended. In a 
feasibility study of transfusion thresholds in 110 patients with acute coronary syndrome or stable 
angina undergoing cardiac catheterization, a liberal transfusion strategy of 10 g/dl was associated 
with a decreased risk of death compared to a restrictive transfusion strategy of 8 g/dl.117 Evidence 
from randomized controlled trials in cardiac surgery refutes findings from observational studies that 
liberal thresholds for RBC transfusion are related to a substantially increased risk of morbidity and 
mortality.118 In the Transfusion Indication Threshold Reduction (TITRe2) trial, 2007 patients with a 
postoperative Hb level of less than 9 g/dl after cardiac surgery were randomized to either a 
restrictive transfusion strategy of less than 7.5 g/dl or a liberal transfusion strategy of less than 9 
g/dl.119 No difference in a composite outcome of serious infection or ischemic events was found but 
it did show that restrictive transfusion resulted in more deaths. NICE, as it stands, recommends that 
RBC transfusion should be considered at a Hb threshold of 8 g/dl in patients with acute coronary 
syndrome, aiming for a concentration target of 8-10 g/dl after transfusion.115       
 
Challenges and practicalities in the implementation of PBM 
 
In view of its demonstrable benefits, there is an increasing awareness of the need to integrate the 
pillars of PBM within routine surgical care. In the US, PBM has been successfully introduced in 
some centers120 while in Western Australia, it has become the standard of care.121 PBM initiatives in 
Europe however has been variable and inconsistent, reflecting the difficulties that can be met with 
its implementation.122 Multiple barriers, including lack of knowledge, interdisciplinary 




National health care quality change initiatives set the agenda for change, but the patient centered 
approach to PBM needs to be delivered in a way that is also hospital centered so it is practical, 
feasible and socially acceptable with each institution. 
 
In each institution, clinical champions and strong leadership are needed to establish PBM and 
overcome clinical inertia. Hospital Transfusion Committees (HTC) could offer a multidisciplinary 
leadership role, providing effective hospital governance that would cater for all transfusion related 
issues within the institution. The HTC oversee the implementation of national policies on blood 
transfusion and guidelines on the clinical use of blood. One discipline cannot manage the shift in 
the paradigm alone and hence consensus among disciplines on the bundles of diagnostic and 
therapeutic interventions is required.127 Cooperation and engagement of the main stakeholders, such 
as health authorities, hospital administrators, blood services, patients and practitioners, can 
harmonize their different backgrounds and philosophies and pave the foundation for the effective 
institution of PBM. Communication and understanding the motivational frameworks and principles 
of various specialities such as anesthesiology, hematology and surgery is critical to success. In order 
to evaluate the cost effectiveness of the introduction of PBM, registries for systematic data 
collection should be considered. Moreover, incentives for the adoption of newer measures and 
disincentives against older practices are needed. Otherwise, the assumed initial costs of setting up a 
PBM program could discourage individual hospitals, even though PBM is expected to decrease 
longer term health care costs.  
 
Characterization of the current practice of PBM at each hospital is needed and benchmarking of 
performance should be instituted to identify areas of need. Information should then be shared with 
stakeholders to enable the planning of appropriate interventions which should be put in place under 
the precondition of applied change management principles after the identification of drivers for 
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change. Constructive criticism and suggestions from the multidisciplinary field are crucial to adjust 
and improve the program and should be welcomed.  
 
Barriers to effective PBM implementation need be recognised and acted upon. Before practice 
guidelines can affect patient outcome, doctors of all specialities must have a shared understanding 
of the evidence and principles driving the paradigm shift towards the practice of PBM. Doctors, 
familiar with the ease and established use of ABT, may not appreciate the risks associated with 
transfusion and the benefits related to PBM. Education and training should be considered to 
increase awareness of the clinical implications of anemia and the need for alternatives to 
transfusion. Once any deficiencies in underlying knowledge have been addressed, their attitude and 
finally behavior should change.128 All recommendations and standard operating procedures must be 
easily accessible and aimed at supporting clinical judgement as the cornerstone of patient care. An 
increased appropriateness of RBC utilization, for example, can be encouraged by the introduction of 
electronic real-time clinical decision support systems.129  
 
Individualized multimodal PBM care bundles, defined by the Institute for Healthcare Improvement 
as a straightforward set of evidence based interventions that when implemented together will result 
in significantly better, more penetrating and sustainable outcomes than when implemented 
individually,130 could provide a clinical and pragmatic template for hospitals to follow.131 Outside 
PBM, such care bundles have improved compliance with guidelines and resulted in a beneficial 
impact on care processes and outcomes.132-134  
 
Practice needs to be continuously audited and progress monitored to achieve sustainability. Focus 
should be shifted to the reporting of data on transfusion rates and patient outcomes. Iterative 
feedback should serve to reinforce the attitudes and motivations of the main stakeholders. 
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Institutions must collaborate and learn from centers of excellence in PBM in order to accelerate 




It is clear that the establishment of PBM offers the prospect of reduced risk and improved patient 
outcomes in perioperative pathways. All three pillars of PBM are equally important and can 
structure the decisions and interventions relating to anemia and blood transfusion. A more 
considered approach to blood transfusion, acknowledging its risks, preventatives and alternatives 
should be adopted. Collaborative and continuous efforts to translate PBM guidelines into clinical 
practice, if done in an engaged, multidisciplinary, organized and structured way, could make PBM 
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